|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2008-2-18
|
|
pubmed:abstractText |
Androgen-deprivation therapy (ADT) is the most common and effective systemic therapy for advanced prostate cancer. We hypothesized that germline genetic variation in the androgen axis would improve the efficacy of ADT.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
1527-7755
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
20
|
|
pubmed:volume |
26
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
842-7
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:18281655-Adult,
pubmed-meshheading:18281655-Aged,
pubmed-meshheading:18281655-Aged, 80 and over,
pubmed-meshheading:18281655-Androgen Antagonists,
pubmed-meshheading:18281655-Androgens,
pubmed-meshheading:18281655-Antineoplastic Agents, Hormonal,
pubmed-meshheading:18281655-Humans,
pubmed-meshheading:18281655-Kaplan-Meier Estimate,
pubmed-meshheading:18281655-Male,
pubmed-meshheading:18281655-Middle Aged,
pubmed-meshheading:18281655-Multivariate Analysis,
pubmed-meshheading:18281655-Neoplasm Staging,
pubmed-meshheading:18281655-Neoplasms, Hormone-Dependent,
pubmed-meshheading:18281655-Polymorphism, Genetic,
pubmed-meshheading:18281655-Prostate-Specific Antigen,
pubmed-meshheading:18281655-Prostatic Neoplasms
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation therapy in men with prostate cancer.
|
|
pubmed:affiliation |
Dana-Farber Cancer Institute, Dana 710-C, 44 Binney St, Boston, MA 02115, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Research Support, N.I.H., Extramural
|
